Showing results (1181-1190 of 1,486) with videos related to

Sort By:
Pageof 149
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|June 10, 2022
Safety assessment of the insecticidal protein IPD079Ea from the fern, Ophioglossum pendulumAnne B Carlson, Carey A Mathesius, Stephen Ballou, et al.
Neurological Research and Practice|December 16, 2020
Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areasAndreas Thimm, Saskia Bolz, Michael Fleischer, et al.
Human Gene Therapy|August 9, 2022
Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular AtrophyBenjamin Stolte, Olivia Schreiber-Katz, René Günther, et al.
Clinical and Translational Radiation Oncology|December 15, 2020
Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac - Feasibility, workflow data and patient acceptanceCihan Gani, S Boeke, H McNair, et al.
Helicobacter|December 18, 2002
Oxidative stress in gastric mucosa of asymptomatic humans infected with Helicobacter pylori: effect of bacterial eradicationC P Felley, B Pignatelli, G D Van Melle, et al.
Journal of Medical Virology|May 29, 2009
Two decades of hepatitis B infections among drug users in Amsterdam: are they still a high-risk group?Robin van Houdt, Charlotte H S B van den Berg, Ineke G Stolte, et al.
Virology|November 26, 2008
Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaquesReiner Schulte, You-Suk Suh, Ulrike Sauermann, et al.
Helicobacter|November 9, 2011
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infectionStephan Miehlke, Susanne Krasz, Wulf Schneider-Brachert, et al.
Inflammatory Bowel Diseases|March 24, 2010
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitisTilo Andus, Andreas Kocjan, Moritz Müser, et al.
Cancers|August 12, 2023
Evaluation of CIN2/3 Lesion Regression in GynTect<sup>®</sup> DNA Methylation-Marker-Negative Patients in a Longitudinal StudyHeike Hoyer, Claudia Stolte, Gerd Böhmer, et al.
Pageof 149